Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [06.01.2019] – [Specific research] sallieqhome:starting:physician:reluctant [07.19.2019] – [Specific research] sallieq
Line 190: Line 190:
  
  
-Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}})) PMID 24772521+Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{pubmed>long:24772521}}))  //  Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//
  
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.